Disclosure of the results for the second quarter (mid-year) of the fiscal year ending December 2026. Highlights sales, operating income, ordinary income, net income, and the financial position. The balance sheet includes details of current assets, fixed assets, liabilities, capital structure, and cash flows. While the full-year outlook is disclosed in a separate document, this summary notes interim results and year-over-year variances.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4896","jir_company_name":"Kei Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4896-20260813-01.pdf","jir_short_summary":"Disclosure of the results for the second quarter (mid-year) of the fiscal year ending December 2026. Highlights sales, operating income, ordinary income, net income, and the financial position. The balance sheet includes details of current assets, fixed assets, liabilities, capital structure, and cash flows. While the full-year outlook is disclosed in a separate document, this summary notes interim results and year-over-year variances.","jir_summary":"### Performance Overview\nThis financial summary is a document disclosing the results and financial position for the second quarter (mid-year) of the fiscal year ending December 2026. The main indicators such as sales, operating income, ordinary income, and net income are listed as 'Unknown' in the body, and quarterly progress and YoY changes are not explicitly stated in the narrative. Instead, itemized amounts for the assets, liabilities, and net assets sections are presented, with notes on the composition and trends of current assets, fixed assets, current liabilities, fixed liabilities, and net assets. Cash flow items are shown in a table with explanations of the factors driving changes in cash.\n\n### Outlook and Risks\nThe financial summary presents interim results and the breakdown of financial position, but the full-year forecast and future performance outlook require reference to a separate document or next disclosure. The summary includes information on current cash plans and liquidity, major funding requirements and sources of funds, and comments on the continuity of funding stability. Investors should note that the visibility of full-year projections is currently unclear and should monitor forthcoming updates.","jir_financial_highlights":"Sales: Unknown (Year-over-year unknown)\nOperating income: Unknown (Year-over-year unknown)\nOrdinary income: Unknown (Year-over-year unknown)\nNet income: Unknown (Year-over-year unknown)","jir_category":"","jir_hashtags":"#Share Buyback Related, #FinancialSummary, #InterimFinancials","jir_key_figures":"Sales: Unknown (no notation)\nOperating income: Unknown (no notation)\nOrdinary income: Unknown (no notation)\nNet income: Unknown (no notation)\nTotal assets: Unknown\nTotal equity: Unknown\nCash and cash equivalents: Unknown","jir_meta_title":"Kei Pharma Co., Ltd. Financial Summary for the Second Quarter of the Fiscal Year Ending December 2026 | Interim results with unknown elements","jir_meta_description":"Kei Pharma Co., Ltd. releases the Financial Summary for the second quarter of the fiscal year ending December 2026. While specific sales and profit figures are unknown, assets, liabilities, and cash flows are disclosed. The full-year outlook will be updated in a separate document.","jir_og_title":"Kei Pharma Co., Ltd. Second Quarter Financial Summary","jir_og_description":"Release of Kei Pharma's interim financial summary. Main indicators are unknown, but the financial position and cash flow are disclosed.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59253,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-103009","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n